Skip to content
DraconiticResearch
Search Sources API
181,716 studies31 sourcesUpdated 6 min ago
Peer-reviewedCC BYFrontiers in bioengineering and biotechnology

India’s DNA synthesis landscape: regulatory frameworks, industry structure, and biosecurity gaps

  • Suryesh Kumar Namdeo1
  • Mayra Ameneiros2
  1. 1Indian Institute of Science , , ,
  2. 2International Biosecurity and Biosafety Initiative for Science (IBBIS) , ,
Read full textPDFDOICite

Abstract

India is among the world’s largest and fastest-growing bioeconomies and ranks third globally in the number of in-country custom DNA synthesis providers, yet it lacks a dedicated regulatory framework governing the synthesis, sale, and distribution of synthetic nucleic acids. This perspective article examines India’s policy and regulatory landscape for synthetic DNA alongside a comprehensive mapping of the domestic DNA synthesis industry.

Related

  1. Comprehensive regulatory and developmental landscape of cell–scaffold combination therapies for osteoarthritis
    Yunbin Choi, Seungyong Lee, Soobin Moon +5
    Regenerative therapyPeer-reviewedCC BY-NC-NDFull textGeneral medicineEurope PMC
  2. Adverse event reporting in healthcare-Regulatory frameworks, institutional governance, and economic implications with evidence from Poland.
    Jolanta Agnieszka Pacian, Marlena Jolanta Piekut
    Frontiers in public healthPeer-reviewedCC BYFull textEpidemiology & public healthEurope PMCCrossref
  3. Explainable AI in Healthcare: A Holistic View of Technical Approaches, Regulatory Frameworks, Reliable Clinical Implementation Insights and Limitations.
    Guilherme Barbosa, Eduardo Carvalho, Dulce Oliveira +7
    Diagnostics (Basel, Switzerland)Peer-reviewedCC BYFull text1 citedGeneral medicineEurope PMC
  4. Repeat element-anchored enhancer-promoter interactions (REEPIs) shape the regulatory landscape of hormone-resistant breast cancer
    X. SHU, S. Ni, M. Murata +9
    bioRxivPreprintCC BY-NC-NDFull textOncologybioRxiv
  5. Mapping the complement-targeted landscape in igA nephropathy: a systematic review with structured descriptive synthesis
    Xin-Yu Li, Chang-Ying Zhong, Li-Nan Zhang +1
    Frontiers in medicinePeer-reviewedCC BYFull textGeneral medicineEurope PMC

Cite

BibTeXRIS
BibTeX
@article{namdeo2026indias,
  title = {{India’s DNA synthesis landscape: regulatory frameworks, industry structure, and biosecurity gaps}},
  author = {Suryesh Kumar Namdeo and Mayra Ameneiros},
  journal = {Frontiers in bioengineering and biotechnology},
  year = {2026},
  month = oct,
  doi = {10.3389/fbioe.2026.1879032},
  url = {https://europepmc.org/article/PMC/PMC13724442},
  note = {CC BY},
}
RIS
TY  - JOUR
TI  - India’s DNA synthesis landscape: regulatory frameworks, industry structure, and biosecurity gaps
AU  - Suryesh Kumar Namdeo
AU  - Mayra Ameneiros
PY  - 2026
DA  - 2026/10/19
JO  - Frontiers in bioengineering and biotechnology
DO  - 10.3389/fbioe.2026.1879032
UR  - https://europepmc.org/article/PMC/PMC13724442
AB  - India is among the world’s largest and fastest-growing bioeconomies and ranks third globally in the number of in-country custom DNA synthesis providers, yet it lacks a dedicated regulatory framework governing the synthesis, sale, and distribution of synthetic nucleic acids. This perspective article examines India’s policy and regulatory landscape for synthetic DNA alongside a comprehensive mapping of the domestic DNA synthesis industry.
SN  - 2296-4185
ER  -